JP2008542321A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008542321A5 JP2008542321A5 JP2008514011A JP2008514011A JP2008542321A5 JP 2008542321 A5 JP2008542321 A5 JP 2008542321A5 JP 2008514011 A JP2008514011 A JP 2008514011A JP 2008514011 A JP2008514011 A JP 2008514011A JP 2008542321 A5 JP2008542321 A5 JP 2008542321A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- monoclonal antibody
- fragment
- humanized monoclonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 23
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 10
- 210000004602 germ cell Anatomy 0.000 claims description 9
- 102000055277 human IL2 Human genes 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000002864 sequence alignment Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 239000002157 polynucleotide Substances 0.000 claims 9
- 102000040430 polynucleotide Human genes 0.000 claims 9
- 108091033319 polynucleotide Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 4
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 206010065159 Polychondritis Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000006454 hepatitis Diseases 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- 208000009169 relapsing polychondritis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000037408 Device failure Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010073696 Wallerian degeneration Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000003229 acute pancreatitis Diseases 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000399 orthopedic effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 230000008734 wallerian degeneration Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 208000007222 Physiological Sexual Dysfunction Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05011845.4 | 2005-06-01 | ||
| EP05011845 | 2005-06-01 | ||
| PCT/EP2006/005194 WO2006128690A1 (en) | 2005-06-01 | 2006-05-31 | Anti-il2 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008542321A JP2008542321A (ja) | 2008-11-27 |
| JP2008542321A5 true JP2008542321A5 (enExample) | 2012-08-09 |
| JP5414271B2 JP5414271B2 (ja) | 2014-02-12 |
Family
ID=37025008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008514011A Expired - Fee Related JP5414271B2 (ja) | 2005-06-01 | 2006-05-31 | 抗ｉｌ２抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7964707B2 (enExample) |
| EP (1) | EP1888644A1 (enExample) |
| JP (1) | JP5414271B2 (enExample) |
| KR (1) | KR101340559B1 (enExample) |
| CN (1) | CN101189265B (enExample) |
| AU (1) | AU2006254333B2 (enExample) |
| BR (1) | BRPI0610912A2 (enExample) |
| CA (1) | CA2609234C (enExample) |
| IL (1) | IL187316A0 (enExample) |
| MX (1) | MX2007014565A (enExample) |
| NO (1) | NO20076568L (enExample) |
| NZ (1) | NZ563213A (enExample) |
| RU (1) | RU2425054C2 (enExample) |
| WO (1) | WO2006128690A1 (enExample) |
| ZA (1) | ZA200709456B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2408820A4 (en) * | 2009-03-16 | 2013-01-23 | Cephalon Australia Pty Ltd | HUMANIZED ANTIBODIES WITH ANTITUMOR EFFECT |
| AU2010314798B2 (en) * | 2009-11-05 | 2013-10-24 | Teva Pharmaceuticals Australia Pty Ltd | Treatment of cancer involving mutated KRAS or BRAF genes |
| CA2869477C (en) | 2012-04-03 | 2020-06-09 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor c3 antibodies and uses thereof |
| WO2015088348A1 (en) | 2013-12-12 | 2015-06-18 | Umc Utrecht Holding B.V. | Immunoglobulin-like molecules directed against fibronectin-eda |
| US9758578B2 (en) | 2013-12-26 | 2017-09-12 | Mitsubishi Tanabe Pharma Corporation | Human anti-IL-33 neutralizing monoclonal antibody |
| AU2015287227B2 (en) * | 2014-07-10 | 2021-02-18 | Universitat Zurich | Immune-stimulating monoclonal antibodies against human interleukin-2 |
| KR102876923B1 (ko) * | 2015-10-23 | 2025-10-28 | 화이자 인코포레이티드 | 항-il-2 항체 및 조성물 및 이의 용도 |
| BR112018014150A2 (en) | 2016-01-11 | 2018-12-11 | Novartis Ag | immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof |
| CA3029977A1 (en) * | 2016-07-06 | 2018-01-11 | Celgene Corporation | Antibodies with low immunogenicity and uses thereof |
| AU2017335771A1 (en) * | 2016-09-28 | 2019-02-28 | Musc Foundation For Research Development | Antibodies that bind interleukin-2 and uses thereof |
| JP7057980B2 (ja) * | 2017-05-25 | 2022-04-21 | インスティテュート フォー ベーシック サイエンス | 抗－ヒトインターロイキン－２抗体及びその用途 |
| CN115920032A (zh) | 2017-08-31 | 2023-04-07 | 田边三菱制药株式会社 | 含有il-33拮抗剂的子宫内膜异位症治疗剂 |
| KR102789146B1 (ko) * | 2019-06-10 | 2025-04-01 | 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 | 항-cd25 항체 및 이의 적용 |
| CN117157312A (zh) | 2021-03-30 | 2023-12-01 | 豪夫迈·罗氏有限公司 | 蛋白酶活化的多肽 |
| CN116284380A (zh) * | 2021-05-14 | 2023-06-23 | 厦门柏慈生物科技有限公司 | 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途 |
| JP2025534285A (ja) | 2022-09-29 | 2025-10-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ポリペプチド |
| CN115850471A (zh) * | 2022-10-13 | 2023-03-28 | 深圳市百士通科技开发有限公司 | 一种抗人il-2单克隆抗体及其应用 |
| CN119661706B (zh) * | 2024-01-31 | 2025-11-28 | 康立泰生物医药(青岛)有限公司 | 一种抗人白介素2抗体及其应用 |
| CN118515762B (zh) * | 2024-07-23 | 2024-11-01 | 北京百普赛斯生物科技股份有限公司 | 特异性结合il-2的抗体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19651443A1 (de) * | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
| WO2001090193A1 (en) | 2000-05-24 | 2001-11-29 | Smithkline Beecham Corporation | Sialoadhesin factor-3 antibodies |
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| ES2436206T3 (es) * | 2001-11-14 | 2013-12-27 | Janssen Biotech, Inc. | Anticuerpos anti il-6, composiciones, métodos y usos |
| NZ540555A (en) * | 2002-11-15 | 2008-04-30 | Genmab As | Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders |
| NZ545385A (en) * | 2003-08-13 | 2010-12-24 | Novartis Vaccines & Diagnostic | Prion-specific peptide reagents |
-
2006
- 2006-05-31 NZ NZ563213A patent/NZ563213A/en not_active IP Right Cessation
- 2006-05-31 RU RU2007143996/10A patent/RU2425054C2/ru not_active IP Right Cessation
- 2006-05-31 EP EP06743094A patent/EP1888644A1/en not_active Withdrawn
- 2006-05-31 WO PCT/EP2006/005194 patent/WO2006128690A1/en not_active Ceased
- 2006-05-31 CA CA2609234A patent/CA2609234C/en not_active Expired - Fee Related
- 2006-05-31 MX MX2007014565A patent/MX2007014565A/es active IP Right Grant
- 2006-05-31 CN CN2006800197422A patent/CN101189265B/zh not_active Expired - Fee Related
- 2006-05-31 JP JP2008514011A patent/JP5414271B2/ja not_active Expired - Fee Related
- 2006-05-31 AU AU2006254333A patent/AU2006254333B2/en not_active Ceased
- 2006-05-31 US US11/916,017 patent/US7964707B2/en active Active
- 2006-05-31 BR BRPI0610912-8A patent/BRPI0610912A2/pt not_active Application Discontinuation
- 2006-05-31 KR KR1020077030731A patent/KR101340559B1/ko not_active Expired - Fee Related
-
2007
- 2007-10-31 ZA ZA200709456A patent/ZA200709456B/xx unknown
- 2007-11-12 IL IL187316A patent/IL187316A0/en unknown
- 2007-12-19 NO NO20076568A patent/NO20076568L/no not_active Application Discontinuation